Table 4 Comparison of 7 recent studies with mid- and long-term follow-up of eyes treated with diode-laser cyclophotocoagulation
| Study | Country | Follow-up (months) | No. of eyes | Diagnosis | % Refractory glaucoma | % Neovasc glaucoma | % Primary glaucoma | Mean IOP pretreatm | Mean IOP end of FU | % IOP reduction | Overall success rate (%) | Definition of success | Re-treatment rate (%) | Response rate after 1st CPC (%) | Response rate after 2nd CPC (%) | No. of treatments per eye | No. of treatments (range) | No. of burns per treatment episode | Mean energy per treatment episode (J) | Mean total energy per eye (J) | VA stable (%) | VA improved (%) | VA worsened (%) |
| Kramp et al19 | Germany | 13.9 | 193 | Primary and secondary glaucoma | 6.2 | 64.8* | 24.6 | 19.3 | 21.5* | 76.4 | 10 to 22 mm Hg | 21.2 | 68.9 | 1.3 | 1 to 6 | 24 to 30 | 92.4* | 120.1* | |||||
| Grueb et al18 | Germany | 24.0 | 90 | Primary glaucoma | 0 | 100 | 21.0 | 16.0 | 23.8 | 36.7 | 4 to 18 mm Hg | 30.0 | 1.3 | 1 to 3 | 15 to 20 | 80.0 | 104.0* | ||||||
| Ansari and Gandhewar20 | UK | 12.5 | 74 | Refractory and non-refractory glaucom | 50 | 31 | 40.3 | 21.1 | 45.1 | 82.0 | 30% reduction | 1.4† | 82** | 1.01 | 1 to 2 | 30 (4.5) | 124.1* | 124.1* | |||||
| Noureddin et al15 | Lebanon | 13.7 | 36 | Refractory glaucoma | 100 | 16.6 | 25 | 35.8 | 19.1 | 53 | 72.2 | ?? 21 mm Hg | 25.0 | 1.25 | 1 to 2 | 26 to 28 | 121.5* | 151.9* | 44 | 33 | 22 | ||
| Murphy et al16 | UK | 17.0 | 263 | Refractory glaucoma | 100 | 46.4 | 18.6 | 40.7 | 17.7 | 52.6 | 79.5 | 5 to 21 mm Hg | 34.2 | 58.9 | 81.3 | 1.5 | 1 to 7 | - | 104.1 | 155.2 | 75 | 5 | 20 |
| Pucci et al17 | Italy | 26.0 | 120 | Refractory glaucoma | 100 | 12.5 | 52.5 | 30.4 | 20.3 | 35 | 76‡ | ?? 21 mm Hg | 45.8 | 54.1 | 1.7 | 1 to 5 | 10 (1.8) | 43.6* | 75.2* | 55 | 21 | 24 | |
| Iliev and Gerber (this study) | Switzerland | 30.1 | 131 | Refractory glaucoma | 100 | 61.1 | 12.2 | 37.7 | 15.3 | 55 | 69.5 | 6 to 21 mm Hg | 38.9 | 55.0 | 80.2 | 1.54 | 1 to 6 | 22 (5.6) | 86.8 | 133.9 | 55 | 11 | 34 |
-
*Calculated, based on the data in the paper; †only one eye was re-treated; ‡calculated according to table 2 in the paper; **see the definition of success and the end IOP.
